About OsciFlex
OsciFlex LLC was founded in 2017 by John Welsh, PhD and Mark Kahn, MD at the University of Pennsylvania. Dr. Welsh and Dr. Kahn uncovered key findings related to the molecular pathology of venous thrombosis. OsciFlex was founded to leverage novel science to create improved therapies for patients to prevent and treat venous disease.
Meet The Team
Mark Kahn,MD
Chief Medical Officer and Co-Founder
John Welsh, PhD
CEO and Co-Founder
A novel approach to preventing Venous thromboembolism (VTE)
New treatments for chronic venous insufficiency
Therapies to prevent physical complications from prolonged immobility
Core Values
Objectives
Company Milestones
2019:
-
NSF SBIR PHASE I Grant
-
NIH STTR PHASE 1 Grant
-
Penn Cardiovascular Institute “Dream Team” Award
-
Penn Health Tech Award
-
Basic science publication accept to top journal (JCI 2019)
2021 / 2022:
-
NIH SBIR Phase II Grant awarded
-
File initial patent application for rapid cycling compression technology
-
NSF SBIR Phase II Grand awarded
2024:
-
Raised private seed round of funding​
-
Completed out-licensing of rapid cycling compression technology
Core Values
2025:
-
Raised additional private funding
-
Filed initial patent applications for two additional devices